Merck & Co., Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Merck & Co., Inc. - Product Pipeline Review - 2016', provides an overview of the Merck & Co., Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Merck & Co., Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Merck & Co., Inc. - The report provides overview of Merck & Co., Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Merck & Co., Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Merck & Co., Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Merck & Co., Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Merck & Co., Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Merck & Co., Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 7 Merck & Co., Inc. Snapshot 8 Merck & Co., Inc. Overview 8 Key Information 8 Key Facts 8 Merck & Co., Inc. - Research and Development Overview 9 Key Therapeutic Areas 9 Merck & Co., Inc. - Pipeline Review 21 Pipeline Products by Stage of Development 21 Pipeline Products - Monotherapy 22 Pipeline Products - Combination Treatment Modalities 23 Pipeline Products - Partnered Products 24 Pipeline Products - Out-Licensed Products 28 Merck & Co., Inc. - Pipeline Products Glance 31 Merck & Co., Inc. - Late Stage Pipeline Products 31 Merck & Co., Inc. - Clinical Stage Pipeline Products 34 Merck & Co., Inc. - Early Stage Pipeline Products 38 Merck & Co., Inc. - Drug Profiles 42 (elbasvir + grazoprevir) 42 asenapine maleate 44 bezlotoxumab 45 desloratadine 46 diquafosol tetrasodium 48 fosaprepitant dimeglumine 50 insulin glargine 51 narlaprevir 53 pembrolizumab 54 (actoxumab + bezlotoxumab) 64 (atorvastatin calcium + ezetimibe) 65 (ceftolozane sulfate + tazobactam sodium) 66 (cilastatin sodium + imipenem + relebactam) 68 (doravirine + lamivudine + tenofovir disoproxil fumarate) 69 actoxumab 70 anacetrapib 71 corifollitropin alfa 73 doravirine 75 fidaxomicin 77 letermovir 81 odanacatib 82 omarigliptin 84 posaconazole 86 solithromycin 87 standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract 90 tedizolid phosphate 93 V-212 96 V-920 98 verubecestat 101 vibegron 102 vorinostat 103 (grazoprevir + MK-3682 + MK-8408) 107 BQ-123 108 dalotuzumab 110 elbasvir + grazoprevir + MK-3682 113 grazoprevir 114 lomerizine 116 lonafarnib 117 mirtazapine ODT 119 MK-1029 120 MK-2206 121 MK-2206 + selumetinib sulfate 124 MK-7622 126 MK-8521 127 MK-8628 128 samatasvir 130 temozolomide 132 V-114 134 MK-3682 135 vorapaxar sulfate 137 CB-618 139 insulin human 140 MK-0752 141 MK-1075 143 MK-1248 144 MK-2048 145 MK-2248 146 MK-4166 147 MK-7680 148 MK-8189 149 MK-8242 150 MK-8291 152 MK-8408 153 MK-8507 154 MK-8591 155 MK-8666 156 MK-8723 157 MK-8876 158 Monoclonal Antibody for Autoimmune Diseases 159 NB-1008 160 rituximab biosimilar 161 Small Molecule 1 for Human Cytomegalovirus Infection 162 Small Molecule 2 for Human Cytomegalovirus Infection 163 V-160 164 V-180 165 BNC-375 167 CB-027 168 chikungunya (viral like particles) vaccine 169 DORA-12 170 Drug to Inhibit 11Beta-HSD1 for Hypertension 171 ETP-142 172 GP-4 173 GRA-1 175 J8-CRM197 176 mDX-400 177 MK-0429 178 MK-1966 179 MK-4256 180 MK-8267 181 MK-8745 182 MK-8825 183 MK-8970 184 Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia 185 Monoclonal Antibody for Cancer 186 MRK-003 187 MRK-1777 188 MRLB-11055 189 Proteins for Cancer, Autoimmune and Inflammatory diseases 190 PTC-512 191 PTC-725 192 PTC-971 193 PyP-1 194 respiratory syncytial virus vaccine 195 SCH-412348 196 SCH-546738 197 Small Molecule 3 for Human Cytomegalovirus Infection 198 Small Molecule to Agonize Glucocorticoid Receptor for Respiratory Disorders 199 Small Molecule to Antagonize Glucagon Receptor for Type 2 Diabetes 200 Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Staphylococcus aureus Infection 201 Small Molecule to Inhibit ROMK for Hypertension and Heart Failure 202 Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis 203 Small Molecules for Undisclosed Indications 204 Small Molecules to Agonize GPR119 for Metabolic Disorders 205 Small Molecules to Agonize M1 for Alzheimer's Disease 206 Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease 208 Small Molecules to Block Cav2.2 Channel for Chronic Pain 209 Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases 210 Small Molecules to Inhibit DGAT1 211 Small Molecules to Inhibit DHFR for Septicaemia 212 Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours 213 Small Molecules to Inhibit Prolyl Hydroxylase for Anemia 214 Small Molecules to Inhibit Renin for Hypertension 215 THPP-1 216 TROX-1 217 XEN-445 218 XL-499 219 Drug to Target GPCR for Undisclosed Indication 220 Kibdelomycin A 221 MK-8133 222 Monoclonal Antibodies for Undisclosed Indication 223 Monoclonal Antibody for Neurology 224 SCH-722984 225 Small Molecules to Antagonize Adenosine 2A receptor for Undisclosed Indication 226 Small Molecules to Inhibit Inositol Phosphorylceramide for Fungal Infections 227 Small Molecules to Inhibit IRAK4 for Inflammatory Diseases 228 Small Molecules to Inhibit MAPKAP Kinase 2 for Inflammation 229 Small Molecules to Inhibit NS5A for Hepatitis C 230 Small Molecules to Inhibit PPI for Undisclosed Indication 231 Undisclosed Biosimilars 233 Merck & Co., Inc. - Pipeline Analysis 234 Merck & Co., Inc. - Pipeline Products by Target 234 Merck & Co., Inc. - Pipeline Products by Route of Administration 240 Merck & Co., Inc. - Pipeline Products by Molecule Type 242 Merck & Co., Inc. - Pipeline Products by Mechanism of Action 243 Merck & Co., Inc. - Recent Pipeline Updates 248 Merck & Co., Inc. - Dormant Projects 323 Merck & Co., Inc. - Discontinued Pipeline Products 331 Discontinued Pipeline Product Profiles 333 Merck & Co., Inc. - Company Statement 343 Merck & Co., Inc. - Locations And Subsidiaries 345 Head Office 345 Other Locations & Subsidiaries 345 Appendix 376 Methodology 376 Coverage 376 Secondary Research 376 Primary Research 376 Expert Panel Validation 376 Contact Us 376 Disclaimer 377
List of Tables
Merck & Co., Inc., Key Information 19 Merck & Co., Inc., Key Facts 19 Merck & Co., Inc. - Pipeline by Indication, 2016 21 Merck & Co., Inc. - Pipeline by Stage of Development, 2016 32 Merck & Co., Inc. - Monotherapy Products in Pipeline, 2016 33 Merck & Co., Inc. - Combination Treatment Modalities in Pipeline, 2016 34 Merck & Co., Inc. - Partnered Products in Pipeline, 2016 35 Merck & Co., Inc. - Partnered Products/ Combination Treatment Modalities, 2016 36 Merck & Co., Inc. - Out-Licensed Products in Pipeline, 2016 39 Merck & Co., Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 40 Merck & Co., Inc. - Pre-Registration, 2016 42 Merck & Co., Inc. - Phase III, 2016 43 Merck & Co., Inc. - Phase II, 2016 45 Merck & Co., Inc. - Phase I, 2016 47 Merck & Co., Inc. - Preclinical, 2016 49 Merck & Co., Inc. - Discovery, 2016 52 Merck & Co., Inc. - Pipeline by Target, 2016 245 Merck & Co., Inc. - Pipeline by Route of Administration, 2016 252 Merck & Co., Inc. - Pipeline by Molecule Type, 2016 253 Merck & Co., Inc. - Pipeline Products by Mechanism of Action, 2016 254 Merck & Co., Inc. - Recent Pipeline Updates, 2016 259 Merck & Co., Inc. - Dormant Developmental Projects,2016 334 Merck & Co., Inc. - Discontinued Pipeline Products, 2016 342 Merck & Co., Inc., Subsidiaries 356
Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealanRead More...
Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the demRead More...
Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energRead More...
Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving creamRead More...
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.